Literature DB >> 20442674

Genu recurvatum in cerebral palsy--part A: influence of dynamic and fixed equinus deformity on the timing of knee recurvatum in children with cerebral palsy.

Martin Svehlík1, Ernst B Zwick, Gerhardt Steinwender, Vinay Saraph, Wolfgang E Linhart.   

Abstract

The aim of the study was to confirm the hypothesis of the influence of the dynamic and fixed equinus deformity on the timing of knee recurvation (hyperextension). According to our hypothesis, dynamic equinus is linked to early and fixed equinus and to late knee hyperextension. A group 35 children with cerebral palsy (47 lower limbs) was divided into two subgroups according to the timing of maximum knee hyperextension. Clinical examination confirmed our hypothesis. Gait analysis and musculoskeletal modelling results were compared with 12 normally developing children. Both recurvatum groups had forefoot landing and neither achieved normal ankle dorsiflexion. Electromyographic examination revealed an abnormally high soleus activity in a single stance. Muscle length changes of medial gastrocnemius and soleus were in agreement with our hypothesis. Such a finding might simplify the decision as to which treatment to select for equinus deformity, present in patients with genu recurvatum.

Entities:  

Mesh:

Year:  2010        PMID: 20442674     DOI: 10.1097/BPB.0b013e32833a5f72

Source DB:  PubMed          Journal:  J Pediatr Orthop B        ISSN: 1060-152X            Impact factor:   1.041


  2 in total

1.  Calf lengthening may improve knee recurvatum in specific children with spastic diplegic cerebral palsy.

Authors:  Jeremy Bauer; K Patrick Do; Jing Feng; Michael Aiona
Journal:  J Child Orthop       Date:  2020-08-01       Impact factor: 1.548

2.  The influence of botulinum toxin A injections into the calf muscles on genu recurvatum in children with cerebral palsy.

Authors:  Matthias C M Klotz; Sebastian I Wolf; Daniel Heitzmann; Simone Gantz; Frank Braatz; Thomas Dreher
Journal:  Clin Orthop Relat Res       Date:  2013-03-06       Impact factor: 4.176

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.